Document is current
Any future updates will be listed below
-
Authors
Yamazaki, Susumu https://orcid.org/0000-0003-2327-9297
Izawa, Kazushi https://orcid.org/0000-0003-1080-0936
Matsushita, Masakazu https://orcid.org/0000-0003-3058-5778
Moriichi, Akinori https://orcid.org/0000-0001-5239-1830
Kishida, Dai https://orcid.org/0000-0001-8309-7984
Yoshifuji, Hajime https://orcid.org/0000-0001-7082-4900
Yamaji, Ken https://orcid.org/0000-0002-0565-1828
Nishikomori, Ryuta https://orcid.org/0000-0002-9407-6158
Mori, Masaaki https://orcid.org/0000-0003-2130-4866
Miyamae, Takako https://orcid.org/0000-0002-0568-1496
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (20FE0101)
- License Information
-
More Information
Article History
Received: 19 July 2023
Accepted: 6 August 2023
First Online: 19 August 2023
Declarations
:
: <i>Financial interest</i>s: TM has received speaker’s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Novartis Japan, and Pfizer Japan Inc. TM has received royalties from Chugai Pharmaceutical Co., Ltd. MM belongs to the department that is financially supported by Chugai, UCB Japan, CSL Behring, AbbVie Japan, Japan Blood Products Organization, AYUMI, Nippon Kayaku, and Asahi-Kasei and has received lecture fees from MSD and consulting fees from Daiichi Sankyo and Taisho. HY received funds for a joint study outside of this work from GlaxoSmithKline, an advisory fee from Janssen, and a lecture fee from Chugai.
: This study did not require approval from the Ethics Committee because it consisted of a literature review.
